How Continuous Manufacturing is Transforming Early-Stage Research.
Pharmaceutical innovators face many challenges when developing new products; as such, getting them to market in a timely, safe and cost-effective way is critical. The use of continuous manufacturing technologies can help to overcome some of the most pressing early-stage obstacles.
GEA.com
SHAPING THE FUTURE OF DRUG DEVELOPMENT. How Continuous Manufacturing is Transforming Early-Stage R&D.
What’s driving pharma companies to rethink early-stage development? Today’s innovators are under pressure to move faster—with limited API, tighter budgets, and increasing demand for process understanding from the start. Continuous manufacturing (CM) meets these challenges head-on, enabling agile development and real-time optimization while minimizing waste.
How does the ConsiGma® platform accelerate formulation and process development? ConsiGma® integrates all key operations—from powder to coated tablet—in a single, compact system. With ConsiGma®-1, developers can screen process parameters quickly using just a few hundred grams of material. That means faster formulation cycles, less rework, and quicker paths to clinical trials.
Does continuous mean complex? Not with GEA. The ConsiGma®-1 is a mobile, plug- and-play unit that runs on standard utilities and fits into compact lab spaces. It’s engineered for ease of use—ideal for quick deployment, flexibility, and contained processing when needed.
How do companies move from lab to commercial production without scale-up? GEA’s philosophy is scale-out, not scale-up. Because ConsiGma® systems share the same process design across development and production lines, companies can transition seamlessly by simply running the same process for longer. No need to reinvent the workflow or change equipment.
Is continuous manufacturing only for new products? Not at all. While CM is ideal for new chemical entities (NCEs), it’s also being used to improve lifecycle management of legacy and generic drugs. Many top-tier pharma companies are replacing batch processes with continuous lines as their default R&D and production approach.
Want to test the technology yourself? GEA’s Pharma Solids Center in Belgium offers hands-on access to ConsiGma® units, from lab-scale to production- scale, for process development, trials, and proof-of- concept testing.
READY TO EXPLORE THE FULL STORY? Discover how global pharma leaders are accelerating development, reducing risk, and maximizing R&D ROI with continuous processing.
https://explore.gea.com/simply-better2/continuous-c0ef/the-gea-philosophy-for-rd-with-continuous-processing?fw=c73ab
Read more 2: